Evidence map›Paper›PMID 31803028›Full record

ReviewFrontiers in neuroanatomy2019

Th17 and Cognitive Impairment: Possible Mechanisms of Action.

Virginia Cipollini, Josef Anrather, Francesco Orzi, Costantino Iadecola

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroanatomy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Longitudinal plasma proteomics: relation to incident Alzheimer's disease dementia and biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Immunogenetics of Multiple Sclerosis in Romanian Patients: Preliminary Data.International journal of molecular sciences · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Virginia CipolliniSant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Josef AnratherFeil Family Brain & Mind Research Institute, Weill Cornell Medicine, New York, NY, United States.
Francesco OrziSant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Costantino IadecolaFeil Family Brain & Mind Research Institute, Weill Cornell Medicine, New York, NY, United States.
Sapienza University of Rome · ITCornell University · USWeill Cornell Medicine · US

Funding

Overexpression of the amyloid precursor protein and cerebrovascular regulationR01NS037853 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Costantino Iadecola · 1998 to 2026
$10.6M
Hypertension and neurovascular dysfunctionR37NS089323 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IADECOLA, COSTANTINO · 2015 to 2021
$3.1M
Immunomodulation by Commensal Microbiota: Role in Ischemic Brain InjuryR01NS094507 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANRATHER, JOSEF · 2016 to 2020
$1.9M
NINDS NIH HHS R01 NS037853NINDS NIH HHS R01 NS094507NINDS NIH HHS R37 NS089323
6 · The paper itself

Abstract

T helper 17 (Th17) cells represent a distinct population of immune cells, important in the defense of the organism against extracellular infectious agents. Because of their cytokine profile and ability to recruit other immune cell types, they are highly pro-inflammatory and are involved in the induction of several autoimmune disorders. Recent studies show that Th17 cells and their signature cytokine IL-17 have also a role in a wide variety of neurological diseases. This review article will briefly summarize the evidence linking Th17 cells to brain diseases associated with cognitive impairment, including multiple sclerosis (MS), ischemic brain injury and Alzheimer's disease (AD). We will also investigate the mechanisms by which these cells enter the brain and induce brain damage, including direct effects of IL-17 on brain cells and indirect effects mediated through disruption of the blood-brain barrier (BBB), neurovascular dysfunction and gut-brain axis. Finally, therapeutic prospects targeting Th17 cells and IL-17 will be discussed.

Indexed as

central nervous systemcognitive impairmentIL-17 cytokineimmune systemneuroinflammationTh17 cells

Identifiers

PMID31803028
PMCPMC6877481
OpenAlexW2988417388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.